{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "former-booth",
   "metadata": {},
   "outputs": [],
   "source": [
    "from bs4 import BeautifulSoup\n",
    "import requests\n",
    "\n",
    "req = requests.get('https://www.medrxiv.org/content/10.1101/2021.01.02.20248998v1.full')\n",
    "soup = BeautifulSoup(req.content, 'html.parser')\n",
    "meta = soup.find_all(\"meta\", attrs = {\"name\" : \"citation_reference\"})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "korean-optics",
   "metadata": {},
   "outputs": [],
   "source": [
    " def parseAmpersandCitation(c):\n",
    "    tokens = c.split(\"&\")\n",
    "    tokens = tokens[1].split(\".\")\n",
    "    # author middle initial messes up split on ., sometimes need to go one over\n",
    "    if(len(tokens[1]) < 5):\n",
    "        return tokens[2]\n",
    "    else:\n",
    "        return tokens[1]\n",
    "\n",
    "def parseEtAlCitation(c):\n",
    "    tokens = c.split(\"et al.\")\n",
    "    return tokens[1].split(\".\")[0]\n",
    "\n",
    "def parseSingleAuthorCitation(c):\n",
    "    c = c.replace(\"?\", \".\")\n",
    "    tokens = c.split(\".\")\n",
    "    # author middle initial messes up split on ., sometimes need to go one over\n",
    "    if(len(tokens[1]) < 5):\n",
    "        return tokens[2]\n",
    "    else:\n",
    "        return tokens[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "partial-dollar",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 20, 533–534 (2020). \n",
      ">\n",
      "An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 20, 533–534 (2020). \n",
      ">\n",
      "An interactive web-based dashboard to track COVID-19 in real time \n",
      "\n",
      "\n",
      "\n",
      "Editors. Dying in a Leadership Vacuum. N Engl J Med 383, 1479–1480 (2020). \n",
      ">\n",
      "Dying in a Leadership Vacuum. N Engl J Med 383, 1479–1480 (2020). \n",
      ">\n",
      "Dying in a Leadership Vacuum \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Looi, M.K. Covid-19: Is a second wave hitting Europe? BMJ 371, m4113 (2020). \n",
      ">\n",
      "Covid-19: Is a second wave hitting Europe? BMJ 371, m4113 (2020). \n",
      ">\n",
      "Covid-19: Is a second wave hitting Europe \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Wiersinga, W.J., Rhodes, A., Cheng, A.C., Peacock, S.J. & Prescott, H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 324, 782–793 (2020). \n",
      ">\n",
      "Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 324, 782–793 (2020). \n",
      ">\n",
      "Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review \n",
      "\n",
      "\n",
      "\n",
      "Oran, D.P. & Topol, E.J. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann Intern Med 173, 362–367 (2020). \n",
      ">\n",
      "Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann Intern Med 173, 362–367 (2020). \n",
      ">\n",
      "Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review \n",
      "\n",
      "\n",
      "\n",
      "Havers, F.P. et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med (2020). \n",
      ">\n",
      " Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med (2020). \n",
      ">\n",
      "Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020 \n",
      "\n",
      "\n",
      "\n",
      "Ehrlich, H., Boneva, D. & Elkbuli, A. The intersection of viral illnesses: A seasonal influenza epidemic amidst the COVID-19 pandemic. Ann Med Surg (Lond) 60, 41–43 (2020). \n",
      ">\n",
      "The intersection of viral illnesses: A seasonal influenza epidemic amidst the COVID-19 pandemic. Ann Med Surg (Lond) 60, 41–43 (2020). \n",
      ">\n",
      "The intersection of viral illnesses: A seasonal influenza epidemic amidst the COVID-19 pandemic \n",
      "\n",
      "\n",
      "\n",
      "Tahmasebi, S., Khosh, E. & Esmaeilzadeh, A. The outlook for diagnostic purposes of the 2019-novel coronavirus disease. J Cell Physiol 235, 9211–9229 (2020). \n",
      ">\n",
      "The outlook for diagnostic purposes of the 2019-novel coronavirus disease. J Cell Physiol 235, 9211–9229 (2020). \n",
      ">\n",
      "The outlook for diagnostic purposes of the 2019-novel coronavirus disease \n",
      "\n",
      "\n",
      "\n",
      "Kumar, R., Nagpal, S., Kaushik, S. & Mendiratta, S. COVID-19 diagnostic approaches: different roads to the same destination. Virusdisease 31, 97–105 (2020). \n",
      ">\n",
      "COVID-19 diagnostic approaches: different roads to the same destination. Virusdisease 31, 97–105 (2020). \n",
      ">\n",
      "COVID-19 diagnostic approaches: different roads to the same destination \n",
      "\n",
      "\n",
      "\n",
      "Hellou, M.M. et al. Nucleic-acid-amplification tests from respiratory samples for the diagnosis of coronavirus infections: systematic review and meta-analysis. Clin Microbiol Infect (2020). \n",
      ">\n",
      " Nucleic-acid-amplification tests from respiratory samples for the diagnosis of coronavirus infections: systematic review and meta-analysis. Clin Microbiol Infect (2020). \n",
      ">\n",
      "Nucleic-acid-amplification tests from respiratory samples for the diagnosis of coronavirus infections: systematic review and meta-analysis \n",
      "\n",
      "\n",
      "\n",
      "D’Cruz, R.J., Currier, A.W. & Sampson, V.B. Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Front Cell Dev Biol 8, 468 (2020). \n",
      ">\n",
      "Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Front Cell Dev Biol 8, 468 (2020). \n",
      ">\n",
      "Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) \n",
      "\n",
      "\n",
      "\n",
      "Pecora, N.D. & Zand, M.S. Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning. Clin Lab Med 40, 603–614 (2020). \n",
      ">\n",
      "Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning. Clin Lab Med 40, 603–614 (2020). \n",
      ">\n",
      "Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning \n",
      "\n",
      "\n",
      "\n",
      "Peeling, R.W. et al. Serology testing in the COVID-19 pandemic response. Lancet Infect Dis 20, e245–e249 (2020). \n",
      ">\n",
      " Serology testing in the COVID-19 pandemic response. Lancet Infect Dis 20, e245–e249 (2020). \n",
      ">\n",
      "Serology testing in the COVID-19 pandemic response \n",
      "\n",
      "\n",
      "\n",
      "La Marca, A. et al. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod Biomed Online 41, 483–499 (2020). \n",
      ">\n",
      " Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod Biomed Online 41, 483–499 (2020). \n",
      ">\n",
      "Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays \n",
      "\n",
      "\n",
      "\n",
      "Pickering, S. et al. Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathog 16, e1008817 (2020). \n",
      ">\n",
      " Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathog 16, e1008817 (2020). \n",
      ">\n",
      "Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings \n",
      "\n",
      "\n",
      "\n",
      "Whitman, J.D. et al. Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nat Biotechnol 38, 1174–1183 (2020). \n",
      ">\n",
      " Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nat Biotechnol 38, 1174–1183 (2020). \n",
      ">\n",
      "Evaluation of SARS-CoV-2 serology assays reveals a range of test performance \n",
      "\n",
      "\n",
      "\n",
      "Oliver, S.E. et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep 69, 1922–1924 (2020). \n",
      ">\n",
      " The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep 69, 1922–1924 (2020). \n",
      ">\n",
      "The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020 \n",
      "\n",
      "\n",
      "\n",
      "Jackson, L.A. et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med 383, 1920–1931 (2020). \n",
      ">\n",
      " An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med 383, 1920–1931 (2020). \n",
      ">\n",
      "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report \n",
      "\n",
      "\n",
      "\n",
      "Anderson, E.J. et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med (2020). \n",
      ">\n",
      " Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med (2020). \n",
      ">\n",
      "Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults \n",
      "\n",
      "\n",
      "\n",
      "Walsh, E.E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med (2020). \n",
      ">\n",
      " Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med (2020). \n",
      ">\n",
      "Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates \n",
      "\n",
      "\n",
      "\n",
      "Dagotto, G., Yu, J. & Barouch, D.H. Approaches and Challenges in SARS-CoV-2 Vaccine Development. Cell Host Microbe 28, 364–370 (2020). \n",
      ">\n",
      "Approaches and Challenges in SARS-CoV-2 Vaccine Development. Cell Host Microbe 28, 364–370 (2020). \n",
      ">\n",
      "Approaches and Challenges in SARS-CoV-2 Vaccine Development \n",
      "\n",
      "\n",
      "\n",
      "Poland, G.A., Ovsyannikova, I.G. & Kennedy, R.B. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 396, 1595–1606 (2020). \n",
      ">\n",
      "SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 396, 1595–1606 (2020). \n",
      ">\n",
      "SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates \n",
      "\n",
      "\n",
      "\n",
      "Zohar, T. et al. Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. Cell 183, 1508–1519 e1512 (2020). \n",
      ">\n",
      " Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. Cell 183, 1508–1519 e1512 (2020). \n",
      ">\n",
      "Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality \n",
      "\n",
      "\n",
      "\n",
      "Lucas, C. et al. Kinetics of antibody responses dictate COVID-19 outcome. MedRxiv (2020). \n",
      ">\n",
      " Kinetics of antibody responses dictate COVID-19 outcome. MedRxiv (2020). \n",
      ">\n",
      "Kinetics of antibody responses dictate COVID-19 outcome \n",
      "\n",
      "\n",
      "\n",
      "Wang, H., Ai, J., Loeffelholz, M.J., Tang, Y.W. & Zhang, W. Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervals. Emerg Microbes Infect 9, 2200–2211 (2020). \n",
      ">\n",
      "Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervals. Emerg Microbes Infect 9, 2200–2211 (2020). \n",
      ">\n",
      "Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervals \n",
      "\n",
      "\n",
      "\n",
      "Caini, S. et al. Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. Euro Surveill 25 (2020). \n",
      ">\n",
      " Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. Euro Surveill 25 (2020). \n",
      ">\n",
      "Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications \n",
      "\n",
      "\n",
      "\n",
      "Lisboa Bastos, M. et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ 370, m2516 (2020). \n",
      ">\n",
      " Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ 370, m2516 (2020). \n",
      ">\n",
      "Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis \n",
      "\n",
      "\n",
      "\n",
      "Moura, D.T.H. et al. Diagnostic Characteristics of Serological-Based COVID-19 Testing: A Systematic Review and Meta-Analysis. Clinics (Sao Paulo) 75, e2212 (2020). \n",
      ">\n",
      " Diagnostic Characteristics of Serological-Based COVID-19 Testing: A Systematic Review and Meta-Analysis. Clinics (Sao Paulo) 75, e2212 (2020). \n",
      ">\n",
      "Diagnostic Characteristics of Serological-Based COVID-19 Testing: A Systematic Review and Meta-Analysis \n",
      "\n",
      "\n",
      "\n",
      "Gutierrez-Cobos, A. et al. Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodies. Eur J Clin Microbiol Infect Dis (2020). \n",
      ">\n",
      " Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodies. Eur J Clin Microbiol Infect Dis (2020). \n",
      ">\n",
      "Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodies \n",
      "\n",
      "\n",
      "\n",
      "FDA. EUA Authorized Serology Test Performance. United States Food and Drug Administration https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance (2020). \n",
      ">\n",
      "EUA Authorized Serology Test Performance. United States Food and Drug Administration https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance (2020). \n",
      ">\n",
      "EUA Authorized Serology Test Performance \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Bermingham, W.H., Wilding, T., Beck, S. & Huissoon, A. SARS-CoV-2 serology: Test, test, test, but interpret with caution! Clin Med (Lond) 20, 365–368 (2020). \n",
      ">\n",
      "SARS-CoV-2 serology: Test, test, test, but interpret with caution! Clin Med (Lond) 20, 365–368 (2020). \n",
      ">\n",
      "SARS-CoV-2 serology: Test, test, test, but interpret with caution! Clin Med (Lond) 20, 365–368 (2020) \n",
      "\n",
      "\n",
      "\n",
      "Long, Q.X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26, 845–848 (2020). \n",
      ">\n",
      " Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26, 845–848 (2020). \n",
      ">\n",
      "Antibody responses to SARS-CoV-2 in patients with COVID-19 \n",
      "\n",
      "\n",
      "\n",
      "Lou, B. et al. Serology characteristics of SARS-CoV-2 infection after exposure and postsymptom onset. Eur Respir J 56 (2020). \n",
      ">\n",
      " Serology characteristics of SARS-CoV-2 infection after exposure and postsymptom onset. Eur Respir J 56 (2020). \n",
      ">\n",
      "Serology characteristics of SARS-CoV-2 infection after exposure and postsymptom onset \n",
      "\n",
      "\n",
      "\n",
      "Zhao, J. et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 71, 2027–2034 (2020). \n",
      ">\n",
      " Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 71, 2027–2034 (2020). \n",
      ">\n",
      "Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019 \n",
      "\n",
      "\n",
      "\n",
      "Tenny, S. & Hoffman, M.R. Prevalence. StatPearls: Treasure Island (FL), 2020. \n",
      ">\n",
      "Prevalence. StatPearls: Treasure Island (FL), 2020. \n",
      ">\n",
      "Prevalence \n",
      "\n",
      "\n",
      "\n",
      "Theel, E.S. et al. The Role of Antibody Testing for SARS-CoV-2: Is There One? J Clin Microbiol 58 (2020). \n",
      ">\n",
      " The Role of Antibody Testing for SARS-CoV-2: Is There One? J Clin Microbiol 58 (2020). \n",
      ">\n",
      "The Role of Antibody Testing for SARS-CoV-2: Is There One \n",
      "\n",
      "\n",
      "\n",
      "Jorfi, M. et al. Diagnostic technology for COVID-19: comparative evaluation of antigen and serology-based SARS-CoV-2 immunoassays, and contact tracing solutions for potential use as at-home products. MedRxiv (2020). \n",
      ">\n",
      " Diagnostic technology for COVID-19: comparative evaluation of antigen and serology-based SARS-CoV-2 immunoassays, and contact tracing solutions for potential use as at-home products. MedRxiv (2020). \n",
      ">\n",
      "Diagnostic technology for COVID-19: comparative evaluation of antigen and serology-based SARS-CoV-2 immunoassays, and contact tracing solutions for potential use as at-home products \n",
      "\n",
      "\n",
      "\n",
      "Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40, 373–383 (1987). \n",
      ">\n",
      "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40, 373–383 (1987). \n",
      ">\n",
      "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation \n",
      "\n",
      "\n",
      "\n",
      "Norman, M. et al. Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19. Nat Biomed Eng (2020). \n",
      ">\n",
      " Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19. Nat Biomed Eng (2020). \n",
      ">\n",
      "Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19 \n",
      "\n",
      "\n",
      "\n",
      "Tian, X. et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 9, 382–385 (2020). \n",
      ">\n",
      " Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 9, 382–385 (2020). \n",
      ">\n",
      "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody \n",
      "\n",
      "\n",
      "\n",
      "Hernaez, R. & Thrift, A.P. High Negative Predictive Value, Low Prevalence, and Spectrum Effect: Caution in the Interpretation. Clin Gastroenterol Hepatol 15, 1355–1358 (2017). \n",
      ">\n",
      "High Negative Predictive Value, Low Prevalence, and Spectrum Effect: Caution in the Interpretation. Clin Gastroenterol Hepatol 15, 1355–1358 (2017). \n",
      ">\n",
      "High Negative Predictive Value, Low Prevalence, and Spectrum Effect: Caution in the Interpretation \n",
      "\n",
      "\n",
      "\n",
      "Kissler, S.M., Tedijanto, C., Goldstein, E., Grad, Y.H. & Lipsitch, M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 368, 860–868 (2020). \n",
      ">\n",
      "Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 368, 860–868 (2020). \n",
      ">\n",
      "Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period \n",
      "\n",
      "\n",
      "\n",
      "Alter, G. & Seder, R. The Power of Antibody-Based Surveillance. N Engl J Med 383, 1782–1784 (2020). \n",
      ">\n",
      "The Power of Antibody-Based Surveillance. N Engl J Med 383, 1782–1784 (2020). \n",
      ">\n",
      "The Power of Antibody-Based Surveillance \n",
      "\n",
      "\n",
      "\n",
      "Neagu, M. The bumpy road to achieve herd immunity in COVID-19. J Immunoassay Immunochem, 1–18 (2020). \n",
      ">\n",
      "The bumpy road to achieve herd immunity in COVID-19. J Immunoassay Immunochem, 1–18 (2020). \n",
      ">\n",
      "The bumpy road to achieve herd immunity in COVID-19 \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Nilles, E.J. et al. Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2. medRxiv (2020). \n",
      ">\n",
      " Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2. medRxiv (2020). \n",
      ">\n",
      "Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2 \n",
      "\n",
      "\n",
      "\n",
      "Corbett, K.S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020). \n",
      ">\n",
      " SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020). \n",
      ">\n",
      "SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness \n",
      "\n",
      "\n",
      "\n",
      "Badnjevic, A., Pokvic, L.G., Dzemic, Z. & Becic, F. Risks of emergency use authorizations for medical products during outbreak situations: a COVID-19 case study. Biomed Eng Online 19, 75 (2020). \n",
      ">\n",
      "Risks of emergency use authorizations for medical products during outbreak situations: a COVID-19 case study. Biomed Eng Online 19, 75 (2020). \n",
      ">\n",
      "Risks of emergency use authorizations for medical products during outbreak situations: a COVID-19 case study \n",
      "\n",
      "\n",
      "\n",
      "Tan, S.S., Chew, K.L., Saw, S., Jureen, R. & Sethi, S. Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results. J Clin Pathol (2020). \n",
      ">\n",
      "Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results. J Clin Pathol (2020). \n",
      ">\n",
      "Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results \n",
      "\n",
      "\n",
      "\n",
      "Gill, D. & Ponsford, M.J. Testing for antibodies to SARS-CoV-2. BMJ 371, m4288 (2020). \n",
      ">\n",
      "Testing for antibodies to SARS-CoV-2. BMJ 371, m4288 (2020). \n",
      ">\n",
      "Testing for antibodies to SARS-CoV-2 \n",
      "\n",
      "\n",
      "\n",
      "Kullar, R. et al. Racial Disparity of Coronavirus Disease 2019 in African American Communities. J Infect Dis 222, 890–893 (2020). \n",
      ">\n",
      " Racial Disparity of Coronavirus Disease 2019 in African American Communities. J Infect Dis 222, 890–893 (2020). \n",
      ">\n",
      "Racial Disparity of Coronavirus Disease 2019 in African American Communities \n",
      "\n",
      "\n",
      "\n",
      "Long, Q.X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26, 1200–1204 (2020). \n",
      ">\n",
      " Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26, 1200–1204 (2020). \n",
      ">\n",
      "Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections \n",
      "\n",
      "\n",
      "\n",
      "Ibarrondo, F.J. et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med 383, 1085–1087 (2020). \n",
      ">\n",
      " Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med 383, 1085–1087 (2020). \n",
      ">\n",
      "Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19 \n",
      "\n",
      "\n",
      "\n",
      "Kutsuna, S., Asai, Y. & Matsunaga, A. Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. N Engl J Med 383, 1695–1696 (2020). \n",
      ">\n",
      "Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. N Engl J Med 383, 1695–1696 (2020). \n",
      ">\n",
      "Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19 \n",
      "\n",
      "\n",
      "\n",
      "Milani, G.P. et al. Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci Rep 10, 20048 (2020). \n",
      ">\n",
      " Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci Rep 10, 20048 (2020). \n",
      ">\n",
      "Serological follow-up of SARS-CoV-2 asymptomatic subjects \n",
      "\n",
      "\n",
      "\n",
      "To, K.K. et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). \n",
      ">\n",
      " COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). \n",
      ">\n",
      "COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing \n",
      "\n",
      "\n",
      "\n",
      "Cohen, J.I. & Burbelo, P.D. Reinfection with SARS-CoV-2: Implications for Vaccines. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). \n",
      ">\n",
      "Reinfection with SARS-CoV-2: Implications for Vaccines. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). \n",
      ">\n",
      "Reinfection with SARS-CoV-2: Implications for Vaccines \n",
      "\n",
      "\n",
      "\n",
      "Mulder, M. et al. Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). \n",
      ">\n",
      " Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). \n",
      ">\n",
      "Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report \n",
      "\n",
      "\n",
      "\n",
      "Hussain, A. et al. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies. Biomed Pharmacother 130, 110559 (2020). \n",
      ">\n",
      " Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies. Biomed Pharmacother 130, 110559 (2020). \n",
      ">\n",
      "Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies \n",
      "\n",
      "\n",
      "\n",
      "WHO. “Immunity passports” in the context of COVID-19. World Health Organization commentaries https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19. (2020). \n",
      ">\n",
      "“Immunity passports” in the context of COVID-19. World Health Organization commentaries https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19. (2020). \n",
      ">\n",
      "“Immunity passports” in the context of COVID-19 \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Waller, J., Rubin, G.J., Potts, H.W.W., Mottershaw, A.L. & Marteau, T.M. ‘Immunity Passports’ for SARS-CoV-2: an online experimental study of the impact of antibody test terminology on perceived risk and behaviour. BMJ Open 10, e040448 (2020). \n",
      ">\n",
      "‘Immunity Passports’ for SARS-CoV-2: an online experimental study of the impact of antibody test terminology on perceived risk and behaviour. BMJ Open 10, e040448 (2020). \n",
      ">\n",
      "‘Immunity Passports’ for SARS-CoV-2: an online experimental study of the impact of antibody test terminology on perceived risk and behaviour \n",
      "\n",
      "\n",
      "\n",
      "Brown, R.C.H., Kelly, D., Wilkinson, D. & Savulescu, J. The scientific and ethical feasibility of immunity passports. Lancet Infect Dis (2020). \n",
      ">\n",
      "The scientific and ethical feasibility of immunity passports. Lancet Infect Dis (2020). \n",
      ">\n",
      "The scientific and ethical feasibility of immunity passports \n",
      "\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "def removeAuthors(s):\n",
    "        \n",
    "    def ampersand(s):\n",
    "        tokens = s.split(\"&\")\n",
    "        return tokens[1].split(\",\", 1)[1].split(\" \", 2)[-1]\n",
    "    \n",
    "    def etAl(s):\n",
    "        tokens = s.split(\"et al.\")[1]\n",
    "        return tokens\n",
    "    \n",
    "    def other(s):\n",
    "        tokens =  s.split(\" \", 1)\n",
    "        if \",\" in tokens[0]:\n",
    "            return tokens[1].split(\" \", 1)[1]\n",
    "        else:\n",
    "            return tokens[1]\n",
    "\n",
    "    if \"&\" in s:\n",
    "        return ampersand(s)\n",
    "    elif \"et al.\" in s:\n",
    "        return etAl(s)\n",
    "    else:\n",
    "        return other(s)\n",
    "\n",
    "def removeJournal(s):\n",
    "    s = s.replace(\"?\", \".\")\n",
    "    return s.split(\".\", 1)[0].strip()\n",
    "\n",
    "for m in meta:  \n",
    "    test = m['content']\n",
    "    if \"&\" in test:\n",
    "        print(test, \"\\n>\")\n",
    "        new = removeAuthors(test)\n",
    "        print(new, \"\\n>\")\n",
    "        print(removeJournal(new), \"\\n\\n\\n\")\n",
    "    elif \"et al.\" in test:\n",
    "        print(test, \"\\n>\")\n",
    "        new = removeAuthors(test)\n",
    "        print(new, \"\\n>\")\n",
    "        print(removeJournal(new), \"\\n\\n\\n\")\n",
    "    else:\n",
    "        print(test, \"\\n>\")\n",
    "        new = removeAuthors(test)\n",
    "        print(new, \"\\n>\")\n",
    "        print(removeJournal(new), \"\\n\\n\\n\")\n",
    "        print(\"\\n\\n\\n\")\n",
    "        \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "entitled-expert",
   "metadata": {},
   "outputs": [],
   "source": [
    "cit = [removeJournal(removeAuthors(m['content'])).strip() for m in meta]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "handmade-bridges",
   "metadata": {},
   "outputs": [],
   "source": [
    "citations = [\n",
    "    'An interactive web-based dashboard to track COVID-19 in real time',\n",
    "    'Dying in a Leadership Vacuum',\n",
    "    'Covid-19: Is a second wave hitting Europe?',\n",
    "    'Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)'\n",
    "    'Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review',\n",
    "    'Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States',\n",
    "    'The intersection of viral illnesses: A seasonal influenza epidemic amidst the COVID-19 pandemic',\n",
    "    'The outlook for diagnostic purposes of the 2019-novel coronavirus disease',\n",
    "    'COVID-19 diagnostic approaches: different roads to the same destination',\n",
    "    'Nucleic-acid-amplification tests from respiratory samples for the diagnosis of coronavirus infections: systematic review and meta-analysis',\n",
    "    'Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)',\n",
    "    'Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning',\n",
    "    'Serology testing in the COVID-19 pandemic response',\n",
    "    'Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays',\n",
    "    'Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings',\n",
    "    'Evaluation of SARS-CoV-2 serology assays reveals a range of test performance',\n",
    "    'The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020',\n",
    "    'An mRNA Vaccine against SARS-CoV-2 - Preliminary Report',\n",
    "    'Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults',\n",
    "    'Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates',\n",
    "    'Approaches and Challenges in SARS-CoV-2 Vaccine Development',\n",
    "    'SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates',\n",
    "    'Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality',\n",
    "    'Kinetics of antibody responses dictate COVID-19 outcome',\n",
    "    'Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervals',\n",
    "    'Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications',\n",
    "    'Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis',\n",
    "    'Diagnostic Characteristics of Serological-Based COVID-19 Testing: A Systematic Review and Meta-Analysis',\n",
    "    'Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodies',\n",
    "    'EUA Authorized Serology Test Performance',\n",
    "    'SARS-CoV-2 serology: Test, test, test, but interpret with caution!',\n",
    "    'Antibody responses to SARS-CoV-2 in patients with COVID-19',\n",
    "    'Serology characteristics of SARS-CoV-2 infection after exposure and postsymptom onset',\n",
    "    'Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019',\n",
    "    'Prevalence',\n",
    "    'The Role of Antibody Testing for SARS-CoV-2: Is There One?',\n",
    "    'Diagnostic technology for COVID-19: comparative evaluation of antigen and serology-based SARS-CoV-2 immunoassays, and contact tracing solutions for potential use as at-home products',\n",
    "    'A new method of classifying prognostic comorbidity in longitudinal studies: development and validation',\n",
    "    'Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19',\n",
    "    'Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody',\n",
    "    'Negative Predictive Value, Low Prevalence, and Spectrum Effect: Caution in the Interpretation',\n",
    "    'Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period',\n",
    "    'The Power of Antibody-Based Surveillance',\n",
    "    'The bumpy road to achieve herd immunity in COVID-19',\n",
    "    'Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2',\n",
    "    'SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness',\n",
    "    'Risks of emergency use authorizations for medical products during outbreak situations: a COVID-19 case study',\n",
    "    'Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results',\n",
    "    'Testing for antibodies to SARS-CoV-2',\n",
    "    'Racial Disparity of Coronavirus Disease 2019 in African American Communities',\n",
    "    'Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections',\n",
    "    'Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19',\n",
    "    'Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19',\n",
    "    'Serological follow-up of SARS-CoV-2 asymptomatic subjects',\n",
    "    'COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing',\n",
    "    'Reinfection with SARS-CoV-2: Implications for Vaccines',\n",
    "    'Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report',\n",
    "    'Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies',\n",
    "    '“Immunity passports” in the context of COVID-19',\n",
    "    'Immunity Passports’ for SARS-CoV-2: an online experimental study of the impact of antibody test terminology on perceived risk and behaviour',\n",
    "    'The scientific and ethical feasibility of immunity passports'  \n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "exceptional-there",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "60\n",
      "61\n",
      "Covid-19: Is a second wave hitting Europe? \n",
      "\n",
      "Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review \n",
      "\n",
      "Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States \n",
      "\n",
      "SARS-CoV-2 serology: Test, test, test, but interpret with caution! \n",
      "\n",
      "The Role of Antibody Testing for SARS-CoV-2: Is There One? \n",
      "\n",
      "Negative Predictive Value, Low Prevalence, and Spectrum Effect: Caution in the Interpretation \n",
      "\n",
      "Immunity Passports’ for SARS-CoV-2: an online experimental study of the impact of antibody test terminology on perceived risk and behaviour \n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(len(citations))\n",
    "print(len(cit))\n",
    "\n",
    "for x in citations:\n",
    "    if x not in cit:\n",
    "        print(x, \"\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "transsexual-science",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<meta content=\"Dong, E., Du, H. &amp; Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 20, 533–534 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Editors. Dying in a Leadership Vacuum. N Engl J Med 383, 1479–1480 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Looi, M.K. Covid-19: Is a second wave hitting Europe? BMJ 371, m4113 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Wiersinga, W.J., Rhodes, A., Cheng, A.C., Peacock, S.J. &amp; Prescott, H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 324, 782–793 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Oran, D.P. &amp; Topol, E.J. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann Intern Med 173, 362–367 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Havers, F.P. et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Ehrlich, H., Boneva, D. &amp; Elkbuli, A. The intersection of viral illnesses: A seasonal influenza epidemic amidst the COVID-19 pandemic. Ann Med Surg (Lond) 60, 41–43 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Tahmasebi, S., Khosh, E. &amp; Esmaeilzadeh, A. The outlook for diagnostic purposes of the 2019-novel coronavirus disease. J Cell Physiol 235, 9211–9229 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Kumar, R., Nagpal, S., Kaushik, S. &amp; Mendiratta, S. COVID-19 diagnostic approaches: different roads to the same destination. Virusdisease 31, 97–105 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Hellou, M.M. et al. Nucleic-acid-amplification tests from respiratory samples for the diagnosis of coronavirus infections: systematic review and meta-analysis. Clin Microbiol Infect (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"D’Cruz, R.J., Currier, A.W. &amp; Sampson, V.B. Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Front Cell Dev Biol 8, 468 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Pecora, N.D. &amp; Zand, M.S. Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning. Clin Lab Med 40, 603–614 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Peeling, R.W. et al. Serology testing in the COVID-19 pandemic response. Lancet Infect Dis 20, e245–e249 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"La Marca, A. et al. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod Biomed Online 41, 483–499 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Pickering, S. et al. Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathog 16, e1008817 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Whitman, J.D. et al. Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nat Biotechnol 38, 1174–1183 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Oliver, S.E. et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep 69, 1922–1924 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Jackson, L.A. et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med 383, 1920–1931 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Anderson, E.J. et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Walsh, E.E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Dagotto, G., Yu, J. &amp; Barouch, D.H. Approaches and Challenges in SARS-CoV-2 Vaccine Development. Cell Host Microbe 28, 364–370 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Poland, G.A., Ovsyannikova, I.G. &amp; Kennedy, R.B. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 396, 1595–1606 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Zohar, T. et al. Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. Cell 183, 1508–1519 e1512 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Lucas, C. et al. Kinetics of antibody responses dictate COVID-19 outcome. MedRxiv (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Wang, H., Ai, J., Loeffelholz, M.J., Tang, Y.W. &amp; Zhang, W. Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervals. Emerg Microbes Infect 9, 2200–2211 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Caini, S. et al. Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. Euro Surveill 25 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Lisboa Bastos, M. et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ 370, m2516 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Moura, D.T.H. et al. Diagnostic Characteristics of Serological-Based COVID-19 Testing: A Systematic Review and Meta-Analysis. Clinics (Sao Paulo) 75, e2212 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Gutierrez-Cobos, A. et al. Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodies. Eur J Clin Microbiol Infect Dis (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"FDA. EUA Authorized Serology Test Performance. United States Food and Drug Administration https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Bermingham, W.H., Wilding, T., Beck, S. &amp; Huissoon, A. SARS-CoV-2 serology: Test, test, test, but interpret with caution! Clin Med (Lond) 20, 365–368 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Long, Q.X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26, 845–848 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Lou, B. et al. Serology characteristics of SARS-CoV-2 infection after exposure and postsymptom onset. Eur Respir J 56 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Zhao, J. et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 71, 2027–2034 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Tenny, S. &amp; Hoffman, M.R. Prevalence. StatPearls: Treasure Island (FL), 2020.\" name=\"citation_reference\"/>\n",
      "<meta content=\"Theel, E.S. et al. The Role of Antibody Testing for SARS-CoV-2: Is There One? J Clin Microbiol 58 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Jorfi, M. et al. Diagnostic technology for COVID-19: comparative evaluation of antigen and serology-based SARS-CoV-2 immunoassays, and contact tracing solutions for potential use as at-home products. MedRxiv (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Charlson, M.E., Pompei, P., Ales, K.L. &amp; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40, 373–383 (1987).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Norman, M. et al. Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19. Nat Biomed Eng (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Tian, X. et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 9, 382–385 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Hernaez, R. &amp; Thrift, A.P. High Negative Predictive Value, Low Prevalence, and Spectrum Effect: Caution in the Interpretation. Clin Gastroenterol Hepatol 15, 1355–1358 (2017).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Kissler, S.M., Tedijanto, C., Goldstein, E., Grad, Y.H. &amp; Lipsitch, M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 368, 860–868 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Alter, G. &amp; Seder, R. The Power of Antibody-Based Surveillance. N Engl J Med 383, 1782–1784 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Neagu, M. The bumpy road to achieve herd immunity in COVID-19. J Immunoassay Immunochem, 1–18 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Nilles, E.J. et al. Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2. medRxiv (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Corbett, K.S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Badnjevic, A., Pokvic, L.G., Dzemic, Z. &amp; Becic, F. Risks of emergency use authorizations for medical products during outbreak situations: a COVID-19 case study. Biomed Eng Online 19, 75 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Tan, S.S., Chew, K.L., Saw, S., Jureen, R. &amp; Sethi, S. Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results. J Clin Pathol (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Gill, D. &amp; Ponsford, M.J. Testing for antibodies to SARS-CoV-2. BMJ 371, m4288 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Kullar, R. et al. Racial Disparity of Coronavirus Disease 2019 in African American Communities. J Infect Dis 222, 890–893 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Long, Q.X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26, 1200–1204 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Ibarrondo, F.J. et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med 383, 1085–1087 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Kutsuna, S., Asai, Y. &amp; Matsunaga, A. Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. N Engl J Med 383, 1695–1696 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Milani, G.P. et al. Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci Rep 10, 20048 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"To, K.K. et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Cohen, J.I. &amp; Burbelo, P.D. Reinfection with SARS-CoV-2: Implications for Vaccines. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Mulder, M. et al. Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Hussain, A. et al. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies. Biomed Pharmacother 130, 110559 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"WHO. “Immunity passports” in the context of COVID-19. World Health Organization commentaries https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19. (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Waller, J., Rubin, G.J., Potts, H.W.W., Mottershaw, A.L. &amp; Marteau, T.M. ‘Immunity Passports’ for SARS-CoV-2: an online experimental study of the impact of antibody test terminology on perceived risk and behaviour. BMJ Open 10, e040448 (2020).\" name=\"citation_reference\"/>\n",
      "<meta content=\"Brown, R.C.H., Kelly, D., Wilkinson, D. &amp; Savulescu, J. The scientific and ethical feasibility of immunity passports. Lancet Infect Dis (2020).\" name=\"citation_reference\"/>\n"
     ]
    }
   ],
   "source": [
    "for m in meta:\n",
    "    print(m)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
